Journal
ONCOTARGETS AND THERAPY
Volume 11, Issue -, Pages 2063-2073Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S161109
Keywords
nuclear factor kappa-B; p65; signaling pathway; cancer; inflammation
Categories
Funding
- National Natural Science Foundation of China [81472595, 81402006]
- Research Project of the Health and Family Planning Commission of Hunan Province [B20180400, B20180582]
Ask authors/readers for more resources
Cancer is a group of cells that malignantly grow and proliferate uncontrollably. At present, treatment modes for cancer mainly comprise surgery, chemotherapy, radiotherapy, molecularly targeted therapy, gene therapy, and immunotherapy. However, the curative effects of these treatments have been limited thus far by specific characteristics of tumors. Abnormal activation of signaling pathways is involved in tumor pathogenesis and plays critical roles in growth, progression, and relapse of cancers. Targeted therapies against effectors in oncogenic signaling have improved the outcomes of cancer patients. NF kappa B is an important signaling pathway involved in pathogenesis and treatment of cancers. Excessive activation of the NF kappa B-signaling pathway has been documented in various tumor tissues, and studies on this signaling pathway for targeted cancer therapy have become a hot topic. In this review, we update current understanding of the NF kappa B-signaling pathway in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available